Leukaemia - acute myeloid leukaemia

The Pharmaceutical Benefits Scheme (PBS) subsidises midostaurin for patients with acute myeloid leukaemia.

Patient eligibility

The PBS subsidises treatment with midostaurin under the National Health Act 1953, section 100 for patients with acute myeloid leukaemia.

Patients must be eligible for the PBS and meet the relevant restriction criteria.

The Schedule of Pharmaceutical Benefits on the PBS website outlines the restrictions for prescribing midostaurin.

Section 100 arrangements

Midostaurin is only available for day admitted patients, non-admitted patients, or patients on discharge attending either:

  • an approved private hospital
  • a public participating hospital
  • a public hospital.

Midostaurin isn't PBS subsidised for hospital in-patients. You must include the hospital name and provider number on the authority application form.

Applications

Induction and consolidation treatment

To apply for induction and consolidation treatment with PBS subsidised midostaurin for acute myeloid leukemia, call the PBS Complex Drugs Programs enquiry line.

Initial treatment

Apply for initial - maintenance therapy - authority approval to prescribe PBS subsidised midostaurin to treat acute myeloid leukaemia in writing and either:

All applications must include the completed:

Initial grandfather treatment

For patients who received non-PBS subsidised midostaurin before 1 December 2018 for acute myeloid leukaemia, apply for initial grandfather - maintenance therapy - authority approval in writing and either:

All applications must include the completed:

Continuing treatment

To apply for continuing - maintenance therapy - PBS subsidised treatment with midostaurin for acute myeloid leukaemia call the PBS Complex Drugs Programs enquiry line.

More information

Call the PBS Complex Drugs Programs enquiry line for more information. 

Page last updated: 22 February 2019

Was this page useful?
Why?
Why not?

Thank you for your feedback.